This review looked at how antibody-based medicines help protect infants from dangerous respiratory viruses like RSV and SARS-CoV-2. The main goal was to see if these treatments could stop severe illness and keep babies out of the hospital.
The results showed very strong protection. Hospitalizations for babies given these medicines dropped by seventy to ninety percent compared to those who did not get the treatment. This means the medicines work very well at preventing serious sickness.
Scientists also checked if the viruses could change to avoid the medicines. There was no sign that the viruses were escaping the protection offered by the drugs. This shows the treatments remain reliable over time.
However, some protection against SARS-CoV-2 became less useful within three years. This happens when viruses change, but the review found no safety problems with the medicines used in babies.